SLEAP SMART:卒中/TIA后使用移动记录仪筛查睡眠呼吸暂停的随机对照试验
该随机对照试验连续纳入250例6个月内发生卒中或短暂性脑缺血发作(TIA)的患者,1:1随机分配至家庭睡眠呼吸暂停监测(HSAT)组或实验室多导睡眠图(iPSG)组。6个月随访时,HSAT组被诊断阻塞性睡眠呼吸暂停(OSA)的比例显著高于iPSG组(48.8%对35.2%,P=0.04),且HSAT组更多患者接受持续气道正压通气治疗、报告嗜睡减轻、日常活动能力改善、睡眠检测体验更好,并具成本效益。
要点
- 卒中/TIA后使用HSAT筛查OSA,诊断率显著高于iPSG(48.8%对35.2%,P=0.04)。
- HSAT组更多患者接受CPAP处方(40.0%对27.2%),嗜睡减轻和日常活动能力改善更显著。
- HSAT组睡眠检测体验良好者比例更高(89.4%对31.1%),且成本效益分析显示HSAT具经济吸引力。
核心结论
- 在卒中/TIA患者中,与iPSG相比,使用HSAT可提高OSA诊断率和治疗率、减轻日间嗜睡、改善功能结局和睡眠检测体验,并可能具经济吸引力。
研究设计与样本
- 随机对照试验,连续纳入250例6个月内发生卒中或TIA的患者,1:1随机分配至HSAT组或iPSG组,意向性治疗分析。
主要发现
- 6个月时HSAT组94例、iPSG组71例完成检测。
- HSAT组OSA诊断率48.8%,显著高于iPSG组的35.2%(P=0.04)。
- HSAT组接受CPAP处方比例40.0%,高于iPSG组的27.2%。
- HSAT组报告睡眠检测体验良好的比例89.4%,高于iPSG组的31.1%。
- HSAT组报告嗜睡显著减轻且日常活动能力改善更明显。
临床怎么用
- 卒中/TIA后可采用HSAT进行OSA筛查,以提高诊断率和治疗启动率。
- HSAT可改善患者睡眠检测体验并可能降低检测成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Poststroke/transient ischemic attack obstructive sleep apnea (OSA) is prevalent, linked with numerous unfavorable health consequences, but remains underdiagnosed. Reasons include patient inconvenience and costs associated with use of in-laboratory polysomnography (iPSG), the current standard tool. Fortunately, home sleep apnea testing (HSAT) can accurately diagnose OSA and is potentially more convenient and cost-effective compared with iPSG. Our objective was to assess whether screening for OSA in patients with stroke/transient ischemic attack using HSAT, compared with standard of care using iPSG, increased diagnosis and treatment of OSA, improved clinical outcomes and patient experiences with sleep testing, and was a cost-effective approach. METHODS: We consecutively recruited 250 patients who had sustained a stroke/transient ischemic attack within the past 6 months. Patients were randomized (1:1) to use of (1) HSAT versus (2) iPSG. Patients completed assessments and questionnaires at baseline and 6-month follow-up appointments. Patients diagnosed with OSA were offered continuous positive airway pressure. The primary outcome was compared between study arms via an intention-to-treat analysis. RESULTS: At 6 months, 94 patients completed HSAT and 71 patients completed iPSG. A significantly greater proportion of patients in the HSAT arm were diagnosed with OSA (48.8% versus 35.2%, P=0.04) compared with the iPSG arm. Furthermore, patients assigned to HSAT, compared with iPSG, were more likely to be prescribed continuous positive airway pressure (40.0% versus 27.2%), report significantly reduced sleepiness, and a greater ability to perform daily activities. Moreover, a significantly greater proportion of patients reported a positive experience with sleep testing in the HSAT arm compared with the iPSG arm (89.4% versus 31.1%). Finally, a cost-effectiveness analysis revealed that HSAT was economically attractive for the detection of OSA compared with iPSG. CONCLUSIONS: In patients with stroke/transient ischemic attack, use of HSAT compared with iPSG increases the rate of OSA diagnosis and treatment, reduces daytime sleepiness, improves functional outcomes and experiences with sleep testing, and could be an economically attractive approach. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02454023.
引用
- Boulos MI, Kamra M, Colelli DR, et al. SLEAP SMART (Sleep Apnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke): A Randomized Controlled Trial. Stroke. 2021. PMID: 34628939. doi:10.1161/STROKEAHA.120.033753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。